Literature DB >> 7898401

Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy.

S D Taylor-Robinson1, J Sargentoni, C D Marcus, M Y Morgan, D J Bryant.   

Abstract

Regional variations in proton magnetic resonance spectroscopy (MRS) were assessed in 26 patients and 14 healthy volunteers using a two dimensional chemical shift imaging technique. Patients were classified as being neuropsychiatrically unimpaired, or as having subclinical or overt chronic hepatic encephalopathy (CHE). Peak area ratios of choline (Cho), glutamine and glutamate (Glx) and N-acetylaspartate (NAA) relative to creatine (Cr) were measured. Significant reductions in mean Cho/Cr and elevations in mean Glx/Cr were observed in the patient population, which correlated with the severity of CHE. There were significant regional variations in these metabolite ratios with the mean Cho/Cr lowest in the occipital cortex and the mean Glx/Cr highest in the basal ganglia. NAA/Cr remained relatively constant in all areas of the brain analysed. The regional variation in the metabolite ratios suggests that spectral information from more than one voxel may be useful in the assessment of patients with CHE.

Entities:  

Mesh:

Year:  1994        PMID: 7898401     DOI: 10.1007/bf02098881

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  30 in total

1.  An image analysis on MR imaging of the brain for hepatic encephalopathy.

Authors:  H W Syh; W K Chu; N Mar; J R McConnell
Journal:  Biomed Sci Instrum       Date:  1991

2.  31P magnetic resonance spectroscopy of the normal human brain: approaches using four dimensional chemical shift imaging and phase mapping techniques.

Authors:  G A Coutts; D J Bryant; A G Collins; I J Cox; J Sargentoni; D G Gadian
Journal:  NMR Biomed       Date:  1989-04       Impact factor: 4.044

3.  Hyperintensity in the globus pallidus on T1-weighted and inversion-recovery MRI: a possible marker of advanced liver disease.

Authors:  A Pujol; F Graus; J Peri; J M Mercader; A Rimola
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

4.  Diagnosis of hepatic encephalopathy by proton magnetic resonance spectroscopy.

Authors:  R Kreis; N Farrow; B D Ross
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

5.  Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma.

Authors:  L Zieve; W M Doizaki; J Zieve
Journal:  J Lab Clin Med       Date:  1974-01

6.  The Revised Kendrick Battery: clinical studies.

Authors:  D C Kendrick; A J Gibson; I C Moyes
Journal:  Br J Soc Clin Psychol       Date:  1979-09

7.  Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy.

Authors:  S D Taylor-Robinson; R A Weeks; J Sargentoni; C D Marcus; D J Bryant; A E Harding; D J Brooks
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

8.  What the clinician can learn from MR glutamine/glutamate assays.

Authors:  R A Chamuleau; D K Bosman; W M Bovée; P R Luyten; J A den Hollander
Journal:  NMR Biomed       Date:  1991-04       Impact factor: 4.044

9.  Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T.

Authors:  J A Brunberg; E Kanal; W Hirsch; D H Van Thiel
Journal:  AJNR Am J Neuroradiol       Date:  1991 Sep-Oct       Impact factor: 3.825

Review 10.  Ammonia: key factor in the pathogenesis of hepatic encephalopathy.

Authors:  R F Butterworth; J F Giguère; J Michaud; J Lavoie; G P Layrargues
Journal:  Neurochem Pathol       Date:  1987 Feb-Apr
View more
  36 in total

Review 1.  Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy.

Authors:  Laurent Spahr; Pierre R Burkhard; Hannelore Grötzsch; Antoine Hadengue
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 2.  The basal ganglia and portal-systemic encephalopathy.

Authors:  K Weissenborn; H Kolbe
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 3.  Proton magnetic resonance spectroscopy in portal-systemic encephalopathy.

Authors:  H Köstler
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 4.  Functional imaging of the brain in patients with liver cirrhosis.

Authors:  Karin Weissenborn; Martin Bokemeyer; Björn Ahl; Daniela Fischer-Wasels; Kathrin Giewekemeyer; Jörg van den Hoff; Herbert Köstler; Georg Berding
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 5.  The role of magnetic resonance imaging and spectroscopy in hepatic encephalopathy.

Authors:  Mark J W McPhail; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2010-03-11       Impact factor: 3.584

6.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

Review 7.  Astroglial dysfunction in hepatic encephalopathy.

Authors:  M D Norenberg
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

8.  Chemical shift magnetic resonance spectroscopy of cingulate grey matter in patients with minimal hepatic encephalopathy.

Authors:  Sergei Mechtcheriakov; Michael Schocke; André Kugener; Ivo W Graziadei; Michael Mattedi; Hartmann Hinterhuber; Wolfgang Vogel; Josef Marksteiner
Journal:  Neuroradiology       Date:  2005-01-18       Impact factor: 2.804

9.  In vivo imaging of cerebral "peripheral benzodiazepine binding sites" in patients with hepatic encephalopathy.

Authors:  A Cagnin; S D Taylor-Robinson; D M Forton; R B Banati
Journal:  Gut       Date:  2005-10-06       Impact factor: 23.059

Review 10.  Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.

Authors:  Salvatore Monaco; Sara Mariotto; Sergio Ferrari; Massimiliano Calabrese; Gianluigi Zanusso; Alberto Gajofatto; Domenico Sansonno; Franco Dammacco
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.